8-K: CooperCompanies Reports Q3 2026 Results, Completes Strategic Review

The Cooper Companies, Inc. announced third quarter 2026 results, reporting a 1% revenue increase and a significant boost in GAAP EPS due to a tax benefit, alongside the completion of a strategic review and an increased share repurchase authorization.

Summary

• The Cooper Companies, Inc. reported fiscal third quarter 2026 results with revenue of $1.066 billion, a 1% increase year-over-year, including 1% organic growth.
• GAAP diluted earnings per share (EPS) was $2.24, significantly up from $0.49 in the prior year's third quarter, primarily due to a $307.2 million discrete tax benefit from a favorable U.K. tax examination.
• Non-GAAP diluted EPS was $1.15, a 4% increase compared to the prior year's third quarter.
• Free cash flow increased by 66% to $273.0 million.
• The company repurchased $339.1 million of common stock during the quarter.
• CooperCompanies announced the completion of its strategic review, concluding that retaining CooperSurgical is the best path forward for shareholder value at this time.
• The share repurchase authorization was increased from $2 billion to $3 billion.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with strong free cash flow and a significant tax benefit boosting GAAP EPS, though organic growth remains modest and some segments face headwinds.

Positives

• Revenue increased 1% year-over-year to $1.066 billion, with 1% organic growth.
• GAAP diluted EPS surged to $2.24, driven by a $307.2 million discrete tax benefit.
• Non-GAAP diluted EPS grew 4% to $1.15.
• Free cash flow saw a substantial increase of 66% to $273.0 million.
• The company repurchased $339.1 million of common stock.
• The share repurchase authorization was expanded by $1 billion, from $2 billion to $3 billion.
• CooperSurgical showed solid fertility growth.
• Gross margin improved to 67% on a GAAP basis.

Negatives

• CooperVision's results were impacted by proactive reductions in U.S. channel inventory, which is expected to continue affecting Q4.
• On a non-GAAP basis, gross margin decreased by 60 basis points due to higher manufacturing costs and unfavorable foreign exchange.
• On a non-GAAP basis, operating margin increased only slightly by 30 basis points.
• CooperVision revenue was comparable to the prior year's third quarter on reported, constant currency, and organic bases.
• Asia Pacific revenue for CooperVision decreased by 10% on a reported basis.

Risks

• Proactive reduction in U.S. channel inventory at CooperVision will continue to impact Q4 results.
• Unfavorable foreign exchange rates are impacting non-GAAP gross and operating margins.
• Potential for adverse changes in global or regional economic conditions, political instability, and natural disasters.
• Impact of international conflicts on global and local economies and financial markets.
• Challenges in managing substantial and expanding international operations and complying with diverse legal and regulatory requirements.
• Potential imposition of tariffs, customs duties, and trade barriers by governments.
• Fluctuations in foreign currency exchange rates and interest rates.
• Risks associated with cybersecurity attacks and data breaches.

Future Outlook

The company updated its fiscal year 2026 guidance, projecting total revenue between $1.057 $1.080 billion for Q4 (0%-2% organic growth) and $4.229 $4.252 billion for the full year (2%-3% organic growth). Non-GAAP diluted EPS for Q4 is expected to be $1.05 $1.09, and $4.51 $4.55 for the full year. The company reaffirms its long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028.

Management Comments

• "This quarter included a number of notable developments including earnings exceeding expectations, record free cash flow, solid fertility growth at CooperSurgical, and a favorable completion of a significant tax matter. At CooperVision, however, we proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4," said Al White, President and CEO of CooperCompanies.
• "Following the completion of the strategic review, we are focused on profitable growth, strong cash flow generation, disciplined capital allocation, and maximizing long-term shareholder value."
• "Our fiduciary duty is to maximize shareholder value, and the Board is collectively aligned that given the offers received, retaining CooperSurgical is the best path forward to creating shareholder value at this time," said Colleen Jay, Chair of the Board.
• "We, with our advisors, ran an extensive process assessing a comprehensive array of strategic alternatives to enhance shareholder value and we believe that with the changes made... the Company is well-positioned for future success."
• "Over the past year, we conducted a rigorous review of every aspect of our business with a singular focus on unlocking value. The process identified meaningful opportunities to enhance execution, sharpen our strategic focus and accelerate innovation."

Industry Context

StockSavvy.ai notes that CooperCompanies operates in the competitive medical device sector, with its CooperVision segment in contact lenses and CooperSurgical in fertility and women's healthcare. The announcement of a completed strategic review and increased share buybacks, while retaining CooperSurgical, suggests a focus on internal value creation and shareholder returns amidst potential market pressures and competitive dynamics, such as a new entrant in the non-hormonal IUD market.

Corporate Governance

Legal Proceedings

• The company mentions 'fertility litigation settlement' as a factor impacting the perceived valuation of CooperSurgical during the strategic review.
• Accrued litigation liability increased significantly from $0.7 million to $316.5 million on the balance sheet.

Stakeholder Impact

• Shareholders: Increased share repurchase authorization and retention of CooperSurgical are intended to enhance long-term shareholder value. The Board's decision to retain CooperSurgical was based on maximizing shareholder value.
• Employees: Potential impacts from operational changes, cost reduction programs, and efficiency initiatives.
• Customers: Inventory and logistics initiatives aim to improve customer service and support future direct shipping capabilities.

Next Steps

• Focus on profitable growth, strong cash flow generation, and disciplined capital allocation.
• Enhance CooperVision's commercial execution, innovation, and organic growth.
• Prioritize organic growth initiatives and operational performance improvements at CooperSurgical.
• Implement inventory and logistics initiatives to improve customer service and operational efficiency.
• Accelerate New Product Introductions and maintain a leading position in the global contact lens market.
• Provide additional updates on operational initiatives, capital allocation priorities, and growth investments in coming quarters.

Key Dates

Recommendation

The company reported mixed results with strong free cash flow and a significant tax benefit boosting GAAP EPS, but modest organic growth and headwinds in CooperVision. The strategic review concluded with retaining CooperSurgical, which was a key point of uncertainty. The increased share repurchase authorization is positive, but the ongoing impact of inventory adjustments in CooperVision and the modest overall growth suggest a 'hold' rating pending clearer signs of accelerated organic growth and improved operational performance across all segments.

Keywords

CooperCompanies, CooperVision, CooperSurgical, Q3 2026 Results, Financial Guidance, Share Repurchase, Strategic Review, Medical Devices